foxo4-dri senolytic human trial 2024 2025 alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice foxo4-dri senolytic peptide human trial
foxo4 dri senolytic peptide human trial 2024 What if aging cells could be removed? As we Rubedo Life Sciences has reached an exciting milestone with the launch of its Phase 1 clinical trial for RLS1496, a firstinclass GPX4 modulator designed to selectively target pathologic senescent cells, a key FOXO4DRI improves the impaired ratio of lung cells. The BLMinduced PF Download Scientific Diagram Targeting Senescence: A Review of Senolytics and Senomorphics in Anti Aging Interventions The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $6.71 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6


